Vaxess Technologies Closes Final Tranche of $8.2 Million Series A and Appoints Dr. Purnanand Sarma to the Board
Vaxess Technologies, a biotechnology company redefining drug delivery with the silk-powered MIMIX smart release patch, today announced it has closed the final tranche of an $8.2 million Series A round. Led by The Engine, the venture capital firm launched by MIT in 2016 to invest in early-stage Tough Tech companies, the round includes participation from Bioinnovation Capital. To date, Vaxess has raised more than $22 million in both grant and equity funding, including backing from the Bill and Melinda Gates Foundation, the National Science Foundation and the National Institutes of Health…..
[Continue reading the full article on Business Wire website ]